drugset / Trial / NCT01162135
Digoxin for Recurrent Prostate Cancer
Phase 2
Completed
16 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effectiveness of dioxin on prohibiting prostate cancer progression as measured by PSADT (prostate-specific antigen doubling time).
Timeline
- Start
- 2010-09
- Primary completion
- 2013-03
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | 125 ug | Oral |
| Subject | Digoxin | Other / unclassified | 250 ug | Oral |
| Subject | Digoxin | Other / unclassified | 500 ug | Oral |